AzTrials
AzTrials

Cholecystitis; Acute, With CholelithiasisPhase 4NCT04290104

Is an Antibiotic Prescription Required After Laparoscopic Cholecystectomy

A Phase 4 study testing 1gr oral ampicillin/sulbactam group in people with Cholecystitis; Acute, With Cholelithiasis, run by Konya Meram State Hospital at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The need for antibiotics to reduce surgical site infection after cholecystectomy for acute calculous cholecystitis is still controversial. The researchers aimed to investigate the effect of antibiotics prescribed on surgical site infection when discharged to patients undergoing laparoscopic cholecystectomy for acute… Read more about this study

Who is it for?
Ages 18 to 100 yearsHealthy volunteers can take part
What is being tested?
1gr oral ampicillin/sulbactam group
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
1 siteTurkey (Türkiye)
Study dates
15 Oct 2020to 31 Dec 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Acute calculous cholecystitis patients over the age of 18 will be included.

Who cannot join

  • Laparoscopic cholecystectomy patients who have been elective for symptomatic cholelithiasis,
  • Patients who are hospitalized with ACC and who undergo late LC, have decompensated systemic disease,
  • Patients with ASA 4,
  • Patients who underwent surgery for early LC due to ACC diagnosis and left laparoscopic method for reasons such as difficult dissection and underwent open cholecystectomy

Trial locations and contacts

1 site in 1 country.

Kemal ARSLAN, MD contact

+905059137791

arslanka74@hotmail.com

Alpaslan ŞAHIN, MD contact

05052955095

drasahin@gmail.com

Turkey (Türkiye)1 site
  • Konya Training and Research Hospital

    Konya, 42090

    Kemal ARSLAN, MD, +905059137791, arslanka74@hotmail.com

    Gurcan Şimşek, MD, +903322210000 ext. 7208, drgurcansimsek@gmail.com

Other trials in Turkey (Türkiye)

About this study

Official title: Is an Antibiotic Prescription Required After Laparoscopic Cholecystectomy for Acute Calculous Cholecystitis?

The need for antibiotics to reduce surgical site infection after cholecystectomy for acute calculous cholecystitis is still controversial. The researchers aimed to investigate the effect of antibiotics prescribed on surgical site infection when discharged to patients undergoing laparoscopic cholecystectomy for acute calculous cholecystitis.

Read the detailed description

Cholecystectomy is the definitive treatment for acute calculous cholecystitis (ACC). In the past, the timing of cholecystectomy has been the subject of debate. Early cholecystectomy performed within 72 hours at the beginning of the disease is preferred to first medical treatment and delayed cholecystectomy 6 to 10 weeks after recovery. In many studies, it suggests early cholecystectomy because it provides a definitive solution, faster recovery times, and more rapid return to work.

Surgical site infections (SSIs) are a significant cause of mortality and morbidity after surgery. In the United States alone, more than 300,000 surgical field infections are seen annually. Again, in the United States alone, the budget spent on surgical site infection reaches $ 10 billion. Antibiotic treatment in ACC patients to prevent surgical site infection is a standard practice in the hospital before and after surgery. However, there is controversy over the use of antibiotics to prevent surgical site infection after discharge. The researchers aimed to investigate the effect of antibiotics prescribed on surgical site infection when discharged to patients undergoing laparoscopic cholecystectomy (LC) for acute calculous cholecystitis.

Patients and Method Patients who were admitted to the General Surgery Clinic with the diagnosis of acute calculous cholecystitis and who underwent early Laparoscopic Cholecystectomy will be included in the study. Patients will be told in detail about the study protocol, and those who accept it will be included in the study. A study consent form, which is written and signed by patients in their handwriting, will be taken. The patients will be staged as Stage 1,2,3 according to the TG13 criteria accepted at the Tokyo 2013 consensus. The anesthesiologist will make ASA classification. Oral intake of the patients will be stopped, and parenteral fluid and anti biotherapy will be applied. The demographic characteristics, comorbidities of the patients, will be recorded in their files, whether they had previous ACC attacks. Patients will be operated within 12-72 hours after hospitalization. Amoxycillin / sulbactam 1 g will be administered parenterally three times a day to patients before and after surgery. Patients included in the post-operative study will be discharged within three days at the latest if the complication has not developed. Just before discharge, the clinical secretary will give a code to each patient with the help of a computer program, and block randomization will be made and divided into two groups. Those who received oral antibiotics (AB group) and those who did not receive antibiotics (HA group).

The primary purpose of antibiotic therapy in ACC is to limit both systemic septic response and local inflammation to prevent SSI in the superficial wound, fascia, and organ cavity. In this study, ampicillin/sulbactam will be used according to the TG18 guidelines (according to recommendation). If the patient is in the AB group, 1 g of ampicillin/sulbactam will be prescribed two times a day and will use for a total of 5-7 days. All demographic features and medical processes of the patients will be recorded electronically with the hospital medical computer program (Deva Data ®).

If SSI is detected by clinical examination and other diagnostic methods (laboratory, ultrasound, and tomography), the antibiotic regimen will be changed in the AB group, and ampicillin/sulbactam will be started in the NA group. Also, superficial and deep SSI will locally be drained, organ SSI will be drained by ultrasonography or tomography-guided.

Sample size calculation: As the reported rate of postoperative SSIs associated with ACC varies between 1% and 15%, it was estimated that 102 patients per group would allow detecting a 10% difference in the rate of complications with 80% power with a confidence interval of 5%. The estimated price of loss to follow-up was 10%; therefore, at least 112 patients were needed to be enrolled for each group.

Being tested
1gr oral ampicillin/sulbactam group
Keywords
cholecystectomy, antibiotic
Medical subject headings
Cholecystitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1gr oral ampicillin/sulbactam groupDrug

    Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.

Study groups in NCT04290104
Study groupRoleWhat they receive
1gr oral ampicillin/sulbactam groupExperimentalThe group to be prescribed 1 g oral ampicillin/sulbactam twice a day while discharged after laparoscopic cholecystectomy due to ACC.
Receives: Drug: 1gr oral ampicillin/sulbactam group
Antibiotic not prescribed groupNo interventionAntibiotics not prescribed when discharged after laparoscopic cholecystectomy due to ACC.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. surgical site infections

    The development of SSI in the operational area or other parts of the body is considered the primary outcome. All patients will be followed up for a postoperative month. It is classified as incisional SSI, CDC guidelines, and superficial, deep, and organ infections.

    Measured: one month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Feb 2020
  2. Study start15 Oct 2020 (estimated)
  3. Primary completion30 Nov 2020 (estimated)
  4. Study completion31 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients discharged after laparoscopic cholecystectomy for acute Calculous Cholecystitis constitutes the study population. The patients discharged are randomized into two groups by the clinical secretary with the help of a computer program. Antibiotics are included in the prescription given to group 1 on the way home. The patient receives 1 gram of Ampicillin/sulbactam twice daily for 5-7 days at home. The patient, who was randomized to the second group, does not have antibiotics on his prescription. After the patients are discharged, they are called for weekly control for a month, and they are examined in terms of surgical site infection. The study reaches the result by making statistical analysis in terms of the rate of surgical site infection between both groups.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
2 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04290104
Sponsor's protocol ID
HSU Konya HPRC
Status last verified
Oct 2020
First submitted
24 Feb 2020
Last updated
5 Oct 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Magill SS, Edwards JR, Fridkin SK; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Survey of health care-associated infections. N Engl J Med. 2014 Jun 26;370(26):2542-3. doi: 10.1056/NEJMc1405194. No abstract available.

    PubMed 24963580
  • Duncan CB, Riall TS. Evidence-based current surgical practice: calculous gallbladder disease. J Gastrointest Surg. 2012 Nov;16(11):2011-25. doi: 10.1007/s11605-012-2024-1. Epub 2012 Sep 18.

    PubMed 22986769

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing 1gr oral ampicillin/sulbactam group in people with Cholecystitis; Acute, With Cholelithiasis, run by Konya Meram State Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kemal ARSLAN, MD (+905059137791, arslanka74@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

surgical site infections (time frame: one month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04290104, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in